Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Viewpoint

Vol. 149 No. 0304 (2019)

Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland

  • Henryk Zulewski
  • Luca Giovanella
  • Stefan Bilz
  • Emanuel Christ
  • Andreas Haldemann
  • Hans Steinert
  • Sabine Weidner
  • Daniel Oertli
  • Frédéric Triponez
  • Thomas Clerici
  • Anna Minder
  • Matthias Dettmer
  • Paul Komminoth
DOI
https://doi.org/10.4414/smw.2019.14700
Cite this as:
Swiss Med Wkly. 2019;149:w14700
Published
27.01.2019

References

  1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133. doi:.https://doi.org/10.1089/thy.2015.0020
  2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W ; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803. doi:.https://doi.org/10.1530/eje.1.02158
  3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–7. doi:.https://doi.org/10.1001/jama.295.18.2164
  4. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”--screening and overdiagnosis. N Engl J Med. 2014;371(19):1765–7. doi:.https://doi.org/10.1056/NEJMp1409841
  5. Bundesamt für Statistik. Krebs in der Schweiz. Stand und Entwicklung von 1983 bis 2007. Neuchâtel: Bundesamt für Statistik; 2011. Available at: https://www.bfs.admin.ch/bfs/de/home/aktuell/neue-veroeffentlichungen.assetdetail.347610.html.
  6. Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ. 2014;348:g3045. doi:.https://doi.org/10.1136/bmj.g3045
  7. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94(8):692–700. doi:.https://doi.org/10.1002/jso.20696
  8. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144(6):980–7, discussion 987–8. doi:.https://doi.org/10.1016/j.surg.2008.08.035
  9. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668–76. doi:.https://doi.org/10.1210/jc.2003-031167
  10. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20(11):1235–45. doi:.https://doi.org/10.1089/thy.2009.0455
  11. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffé S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97(5):1526–35. doi:.https://doi.org/10.1210/jc.2011-2512
  12. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241–60.
  13. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341–9. doi:.https://doi.org/10.1089/thy.2010.0178
  14. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38(1):68–79. doi:.https://doi.org/10.1007/s00268-013-2224-1
  15. Adam MA, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, et al. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J Clin Endocrinol Metab. 2015;100(1):115–21. doi:.https://doi.org/10.1210/jc.2014-3039
  16. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260(4):601–5, discussion 605–7. doi:.https://doi.org/10.1097/SLA.0000000000000925
  17. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–73. doi:.https://doi.org/10.1002/cncr.21055
  18. Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20(11):3477–83. doi:.https://doi.org/10.1245/s10434-013-3125-0
  19. Lang BH, Ng SH, Lau LL, Cowling BJ, Wong KP, Wan KY. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid. 2013;23(9):1087–98. doi:.https://doi.org/10.1089/thy.2012.0608
  20. Shan C-X, Zhang W, Jiang D-Z, Zheng X-M, Liu S, Qiu M. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope. 2012;122(4):797–804. doi:.https://doi.org/10.1002/lary.22162
  21. Zetoune T, Keutgen X, Buitrago D, Aldailami H, Shao H, Mazumdar M, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol. 2010;17(12):3287–93. doi:.https://doi.org/10.1245/s10434-010-1137-6
  22. Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119(6):1135–9. doi:.https://doi.org/10.1002/lary.20236
  23. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117(19):4439–46. doi:.https://doi.org/10.1002/cncr.26070
  24. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):451–7. doi:.https://doi.org/10.1089/thy.2008.0392
  25. Hakala TT, Sand JA, Jukkola A, Huhtala HS, Metso S, Kellokumpu-Lehtinen PL. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Int J Clin Oncol. 2016;21(2):231–9. doi:.https://doi.org/10.1007/s10147-015-0904-6
  26. Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. Clin Endocrinol (Oxf). 2015;83(1):117–23. doi:.https://doi.org/10.1111/cen.12581
  27. Hirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer. Thyroid. 2016;26(8):1110–6. doi:.https://doi.org/10.1089/thy.2016.0037
  28. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023–9. doi:.https://doi.org/10.1001/jamaoncol.2016.0386
  29. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33(1):42–50. doi:.https://doi.org/10.1200/JCO.2014.56.8253
  30. Barbaro D, Incensati RM, Materazzi G, Boni G, Grosso M, Panicucci E, et al. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine. 2014;45(3):462–8. doi:.https://doi.org/10.1007/s12020-013-0029-5
  31. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab. 2012;97(9):E1745–9. doi:.https://doi.org/10.1210/jc.2012-1526
  32. Charles RP, Silva J, Iezza G, Phillips WA, McMahon M. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014;12(7):979–86. doi:.https://doi.org/10.1158/1541-7786.MCR-14-0158-T
  33. Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer. 2015;22(3):419–29. doi:.https://doi.org/10.1530/ERC-15-0057
  34. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946;132(14):838–47. doi:.https://doi.org/10.1001/jama.1946.02870490016004
  35. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63. doi:.https://doi.org/10.1210/jcem.86.4.7407

Most read articles by the same author(s)

1 2 > >>